Company Description
Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health.
It's product portfolio includes DuraGraft, a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure; MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
The company also engages in the development of MAR-FG-001, a fat grafting technology for the use during fat grafting procedures.
Marizyme, Inc. was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018.
The company was incorporated in 2007 and is based in Jupiter, Florida.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | David L. Barthel M.B.A. |
Contact Details
Address: 555 Heritage Drive, Suite 205 Jupiter, Florida 33458 United States | |
| Phone | 561-935-9955 |
| Website | marizyme.com |
Stock Details
| Ticker Symbol | MRZM |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001413754 |
| CUSIP Number | 570372102 |
| ISIN Number | US5703721028 |
| Employer ID | 82-5464863 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David L. Barthel M.B.A. | Chief Executive Officer, Secretary and Director |
| Dr. Catherine J. Pachuk Ph.D. | Executive Vice President and Chief Scientific Officer |
| George Kovalyov C.A., CPA | Chief Financial Officer and Treasurer |
| Dr. Claudio Rigatto M.D. | Chief Medical Officer of My Health Logic |
| Kari Jacobson | Controller |
| Harrison Albert Ross C.F.A. | Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 6, 2024 | 424B3 | Prospectus |
| Feb 6, 2024 | 8-K | Current Report |
| Dec 29, 2023 | 424B3 | Prospectus |
| Dec 28, 2023 | 8-K | Current Report |
| Nov 22, 2023 | 424B3 | Prospectus |
| Nov 21, 2023 | 8-K | Current Report |
| Nov 16, 2023 | 424B3 | Prospectus |
| Nov 14, 2023 | 10-Q | Quarterly Report |
| Oct 24, 2023 | 424B3 | Prospectus |